Skip to main content

Market Overview

Recap: Bio-Techne Q4 Earnings

Share:

Shares of Bio-Techne (NASDAQ:TECH) were unchanged after the company reported Q4 results.

Quarterly Results

Earnings per share fell 20.00% year over year to $1.00, which beat the estimate of $0.75.

Revenue of $175,834,000 declined by 8.26% from the same period last year, which beat the estimate of $163,910,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Bio-Techne hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 04, 2020

Time: 09:00 AM

ET Webcast URL: http://public.viavid.com/player/index.php?id=140692

Technicals

52-week high: $286.68

52-week low: $155.17

Price action over last quarter: Up 22.56%

Company Description

Bio-Techne Corp is a life science manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The protein sciences division's key products (78% of sales) include proteins, antibodies, and assays as well as equipment and associated consumables for protein characterization and analysis. The remaining revenue in the diagnostics and genomics segment is roughly split between manufacturing creates controls, calibrators, and reagents for diagnostic manufacturers combined with proprietary molecular and genetic testing kits. The company is split into two reporting segments namely, Protein Sciences segment and Diagnostics and Genomics segment. The Protein Sciences segment generates maximum revenue for the company.

 

Related Articles (TECH)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com